![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Chapter and Conference Paper
Determining Optimal Placement of Copy Number Aberration Impacted Single Nucleotide Variants in a Tumor Progression History
Intratumoral heterogeneity arises as a result of genetically distinct subclones emerging during tumor progression. These subclones are characterized by various types of somatic genomic aberrations, with single...
-
Article
A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types
Tumor neoepitopes presented by major histocompatibility complex (MHC) class I are recognized by tumor-infiltrating lymphocytes (TIL) and are targeted by adoptive T-cell therapies. Identifying which mutant neoe...
-
Reference Work Entry In depth
Immunology of Melanoma
Historically, the basis of cancer immunology comes from observations of therapy for cancer dating back to antiquity indicating that the immune system can recognize and reject cancers. Ancient Eastern and Weste...
-
Article
Open AccessMemory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients
T cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor infiltrating lymphocytes, but whether such cells can be det...
-
Living Reference Work Entry In depth
Immunology of Melanoma
Historically, the basis of cancer immunology comes from observations of therapy for cancer dating back to antiquity indicating that the immune system can recognize and reject cancers. Ancient Eastern and Weste...
-
Article
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Immunotherapy using either checkpoint blockade or the adoptive transfer of antitumor lymphocytes has shown effectiveness in treating cancers with high levels of somatic mutations—such as melanoma, smoking-indu...
-
Article
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Rosenberg and colleagues review evidence suggesting that T cells that target tumor neoantigens arising from cancer mutations are the main mediators of many effective cancer immunotherapies in humans.
-
Article
Open Access31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
-
Article
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
Steven Rosenberg and colleagues report that PD-1 is a biomarker of CD8+ T cells in the blood that recognize mutated neoantigens in melanoma.
-
Article
Open AccessA Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancers
-
Article
Open AccessDiversity of mutated antigen recognition by tumor infiltrating lymphocytes from patients with metastatic melanoma
-
Article
Open AccessSelection of circulating PD-1+ lymphocytes from cancer patients enriches for tumor-reactive and mutation-specific lymphocytes
-
Article
Open AccessDiscovery and characterization of an immunogenic neoantigen in a patient with metastatic triple negative breast cancer
-
Article
Open AccessIdentification of mutation-specific tumor infiltrating lymphocytes from metastatic ovarian cancer
-
Article
Open AccessPersonalized immunotherapy for non-small cell lung cancer through identification of tumor-specific mutations by next generation sequencing and adoptive transfer of tumor infiltrating lymphocytes that recognize neoantigens
-
Article
Open AccessUnique neoantigens expressed by melanomas and common epithelial cancers presented by multiple HLA alleles can be efficiently identified utilizing peptide prediction algorithms
-
Article
Open AccessHigh frequency CD8+PD-1+ TCR clonotypes isolated from fresh melanomas display anti-tumor activity
-
Article
Open AccessAdoptively transferred tumor-infiltrating T cells target somatic cancer mutations in a human papillomavirus+ cancer patient with complete tumor regression
-
Article
Open AccessStudy and characterization of mutated antigen specific T cells isolated from fresh tumor and peripheral lymphocytes in cancer patients
-
Article
Open AccessTetramer based approach for efficient identification and isolation of neo-antigen specific CD8 T cells from peripheral blood (PBL) of patients with metastatic cancers